…
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
I cannot find reliable public information confirming a NASDAQ-listed company named Disc Medicine Inc. under the ticker IRON, and available databases do not verify the firm's core business or filings. Because verifiable disclosures are lacking, I cannot reliably describe long-term growth drivers or explain why investors may find the company attractive.
The key investment risk is the absence of verifiable public filings or clear corporate identity, which prevents assessment of regulatory, clinical, operational, and financial exposures and increases the chance of misidentification.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | -46.83M | -35.97M | -40.84M |
| Net income | -46.09M | -41.01M | -47.66M |
| Selling general administrative | 14.04M | 5.76M | 5.87M |
| Reconciled depreciation | 0.09M | 0.23M | 0.32M |
| Ebit | -47.56M | -30.93M | -34.04M |
| Ebitda | -47.48M | -25.85M | -33.68M |
| Depreciation and amortization | 0.09M | 5.08M | 0.36M |
| Operating income | -47.48M | -30.93M | -34.04M |
| Other operating expenses | 47.48M | 30.93M | 34.04M |
| Interest expense | 0.74M | 2.16M | 6.83M |
| Interest income | 0.71M | 0.01M | 0.04M |
| Net interest income | 0.71M | -2.14M | -6.79M |
| Income tax expense | -0.74M | 5.04M | 6.83M |
| Total revenue | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 47.48M | 30.93M | 34.04M |
| Total other income expense net | 0.65M | -5.04M | -6.80M |
| Net income from continuing ops | -46.83M | -71.87M | -40.84M |
| Net income applicable to common shares | - | -35.97M | -20.94M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 368.00M | 200.21M | 92.41M | 122.09M |
| Other current assets | 5.28M | 198.49M | 3.47M | 0.13M |
| Total liab | 22.88M | 23.61M | 156.61M | 4.82M |
| Total stockholder equity | 345.12M | 176.60M | -64.20M | 117.27M |
| Other current liab | 21.44M | 6.11M | 6.45M | 0.59M |
| Common stock | 0.00M | - | 0.00M | 112.27M |
| Capital stock | 0.00M | 0.00M | 0.00M | 112.27M |
| Retained earnings | -188.65M | -112.22M | -65.39M | -0.81M |
| Other assets | - | - | 0.18M | 0.06M |
| Cash | 360.38M | 194.61M | 88.04M | 1.21M |
| Total current liabilities | 21.44M | 22.58M | 13.42M | 0.60M |
| Current deferred revenue | -13.29M | - | 4.10M | - |
| Net debt | -358.28M | -193.28M | -86.38M | -1.21M |
| Short term debt | 0.67M | 0.31M | 0.32M | - |
| Short long term debt | - | - | 5.00M | - |
| Short long term debt total | 2.10M | 1.33M | 1.65M | - |
| Other stockholder equity | 533.76M | 288.81M | 1.19M | 5.81M |
| Property plant equipment | - | - | 1.75M | 1.13M |
| Total current assets | 365.66M | 198.49M | 90.48M | 1.34M |
| Net tangible assets | - | - | -64.20M | -28.81M |
| Long term debt | - | - | 0.40M | - |
| Accounts payable | 12.63M | 16.16M | 2.56M | 0.00M |
| Accumulated other comprehensive income | 0.00M | - | - | - |
| Non currrent assets other | 0.23M | 0.12M | 0.18M | 120.75M |
| Non current assets total | 2.33M | 1.71M | 1.93M | 120.75M |
| Capital lease obligations | 2.10M | 1.33M | 1.65M | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | -0.15M | 0.34M | -0.02M |
| Change to liabilities | - | 1.31M | -0.51M |
| Total cashflows from investing activities | - | -0.07M | -0.08M |
| Total cash from financing activities | 148.98M | 89.93M | 34.25M |
| Change to operating activities | - | -0.03M | 1.01M |
| Net income | -46.83M | -35.97M | -40.84M |
| Change in cash | 106.58M | 62.33M | 1.52M |
| Begin period cash flow | 88.21M | 25.89M | 3.31M |
| End period cash flow | 194.79M | 88.21M | 4.83M |
| Total cash from operating activities | -42.25M | -27.53M | -32.71M |
| Issuance of capital stock | 53.50M | 89.86M | 20.08M |
| Depreciation | 0.09M | 0.03M | 0.32M |
| Other cashflows from financing activities | 95.48M | 94.51M | -0.02M |
| Change to netincome | - | 7.12M | 0.45M |
| Capital expenditures | 0.15M | 0.07M | 0.02M |
| Change in working capital | 2.12M | 1.29M | 0.34M |
| Stock based compensation | 2.09M | 0.51M | 0.98M |
| Other non cash items | 0.27M | 1.56M | 6.48M |
| Free cash flow | -42.40M | -27.60M | -32.73M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| IRON Disc Medicine Inc. |
-0.97 1.24% |
77.01 | - | - | - | 2.28 | -4.71 |
| NVO Novo Nordisk A/S |
-0.34 0.86% |
39.09 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-6.95 1.30% |
529.50 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-18.50 1.96% |
927.03 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.
321 Arsenal Street, Watertown, MA, United States, 02472
617 674 9274
78
| Name | Title | Year Born |
|---|---|---|
| Dr. Donald William Nicholson Ph.D. | Executive Chairman | 1959 |
| Dr. William Jacob Savage M.D., Ph.D. | Chief Medical Officer | 1975 |
| Dr. John D. Quisel Esq., J.D., Ph.D. | CEO, President & Director | 1971 |
| Dr. Brian MacDonald ChB, MB, Ph.D. | Founder & Chair of Scientific Advisory Board | 1960 |
| Ms. Jean M. Franchi | Chief Financial Officer | 1966 |
| Mr. Jonathan Yu M.B.A. | Chief Opearating Officer | 1981 |
| Dr. Rahul Khara J.D., Pharm.D. | General Counsel, Compliance Officer & Secretary | 1982 |
| Mr. Srikanth Venkatraman Ph.D. | Senior VP & Head of Chemistry | NA |
| Ms. Hua Yang Ph.D. | Senior Vice President of Nonclinical Development | NA |
| Ms. Pamela Stephenson M.P.H. | Chief Commercial Officer | 1969 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.